SB FIX
Alternative Names: Factor IX gene therapy - Sangamo; SB-FIXLatest Information Update: 30 Mar 2022
At a glance
- Originator Sangamo BioSciences
- Developer Sangamo Therapeutics
- Class Antihaemorrhagics; Gene therapies; Transcription factors; Zinc finger DNA binding proteins
- Mechanism of Action Factor IX replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haemophilia B